**谢渭芬 硕士生导师简介**

1. **个人基本情况**

谢渭芬，男，中共党员，1964年生，现海军军医大学（原第二军医大学）第二附属医院工作，长征医院首席专家，消化内科主任，内镜中心主任，近5年发表第一作者（或通讯作者）统计源期刊论文共 61篇，三大检索收录 36 篇，核心期刊 25 篇。

1. **研究方向**

慢性肝病的基础与临床研究

**3.近5年基金**

1. 肝细胞FOXA2表达影响肝纤维化的分子和细胞机制,国家自然科学基金重点项目（81530019），2016.01-2020.12，327.8万。

2. 低剂量利福昔明预防肝硬化并发症的多中心随机对照研究，申康中心新兴前沿技术联合攻关项目SHDC12016103，2017.01-2019.12，180万。

3. 肝细胞核因子4α治疗肝癌基因工程药物的临床前研究 ，上海市生物医药领域科技支撑项目（15421907700），2015.7-2018.12，50万。

4. 基于hiHep细胞的生物人工肝支持系统治疗肝功能衰竭临床研究，上海市科委重点项目（17411950800），2017.10-2020.09，150万。

5. 肠源性五羟色胺对肝硬化门脉高压症的作用及其机制，国家自然科学基金重点项目（82030021），2021.01-2025.12，297万。

**4.发表SCI论文：**

1. Sun LL, Wang J, Wang YS, Pan X, Luo J, Liu H, Jiang YR, Zhuang X, Lin L, Li GC, Zhao JW, Wang W, Wang YJ, Wang ZH, Shang HB, Chen SS, Chen JL, Xu ZW, Bai YH, Hang H, Xie WF. 15-month health outcomes and the related risk factors of hospitalized COVID-19 patients from onset: a cohort study. Frontiers in Medicine. 2022. Doi:10.3389/fmed.2022.854788 (通讯作者，IF 5.091)
2. Tan W, Wang J, Shi PM, Feng LM, Shi J, Ning BF, Yuan ZL, Zeng X, and Xie WF. Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy. Journal of Clinical and Translational Hepatology 2022. doi: 10.14218/JCTH.2021.00457 (通讯作者，IF4.108)
3. Jian J, Nie MT, Xiang B, Qian H, Yin C, Zhang X, Zhang M\*, Zhu X\*, Xie WF\*. Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids. Frontiers in Pharmacology. 2022 Apr 4;13: 841132. (通讯作者，IF 5.810)
4. Huang R, Zhang X, Gracia-Sancho J, Xie WF. Liver regeneration: cellular origin and molecular mechanisms. Liver Int. 2022 Feb 2. doi: 10.1111/liv.15174. Online ahead of print. （通讯作者，IF 5.828）
5. Zhao Q, Ning BF, Zhou JY, Wang J, Yao YJ, Peng ZY, Yuan ZL, Chen JDZ, Xie WF. Transcutaneous Electrical Acustimulation Ameliorates Motion Sickness Induced by Rotary Chair in Healthy Subjects: A Prospective Randomized Crossover Study. Neuromodulation. 2021 Dec 18:S1094-7159(21)06174-2. （通讯作者，IF 4.722）
6. Huang H, Hu PF, Sun LL, Guo YB, Wang Q, Liu ZM, Yin JZ, Shi PM, Yuan ZL, Xie WF. Treatment of patients with Covid-19 with a high dose of ulinastatin. Exp Ther Med. 2022 Feb;23(2):121. doi: 10.3892/etm.2021.11044. （通讯作者，IF 2.363）
7. Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, Song J, Huang L, Xu Z, Fu JL, Li Y, Xu R, Li TT, Dong J, Cai J, Li G, Xie Y, Shi M, Li Y, Zhang Y, Xie WF, Wang FS. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2022 Jan;75:103789.. （共同通讯作者，IF 8.143）
8. Hu PF, Zeng X, Zou ZY, Tang W, Guo YB, Yuan ZL, Shi PM, Tan Y, Song Y, Shi YQ, Xie WF. The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: a population-based cross-sectional study. HepatoBiliary Surgery and Nutrition. 2021 Dec;10(6):811-824 （通讯作者，IF 7.293）
9. Zeng X, Shi ZW, Yu JJ, Wang LF, Luo YY, Jin SM, Zhang LY, Tan W, Shi PM, Yu H, Zhang CQ, Xie WF. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. Journal of Cachexia, Sarcopenia and Muscle 2021 Dec;12(6):1948-1958 （通讯作者, IF 12.91）
10. Zhang B, Hu Y, Shi X, Li W, Zeng X, Liu F, Chen JDZ, Xie WF. Integrative effects and vagal mechanisms of transcutaneous electrical acustimulation on gastroesophageal motility in patients with gastroesophageal reflux disease. American Journal of Gastroenterology, 2021 Jul 1;116(7):1495-1505.（通讯作者, IF 10.864）
11. Xiao MC, Qian H, Huang CK, Zheng BN, Yan FZ, Liu F, Zhang X, Chen SJ, Luo C, Xie WF. Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy. European Journal of Pharmacology 2021 Sep 5;906:174217.（通讯作者，IF4.432 ）
12. Sun LL, Wang J, Wang YS, Hu PF, Zhao ZQ, Chen W, Ning BF, Yin C, Hao YS, Wang Q, Wang C, Liu YL, Chen C, Yin JZ, Huang H, Xie WF. Symptomatic features and prognosis of 932 hospitalized patients with coronavirus disease 2019 in Wuhan Journal of Digestive Diseases 2021 May;22(5):271-281.（通讯作者，IF 2.325）
13. Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, Wang S, Zhang C, Yuan X, Xu Z, Huang L, Fu JL, Li Y, Zhang Y, Yao WQ, Liu T, Song J, Sun L, Yang F, Zhang X, Zhang B, Shi M, Meng F, Song Y, Yu Y, Wen J, Li Q, Mao Q, Maeurer M, Zumla A, Yao C, Xie WF\*, Wang FS\*. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduction and Targeted Therapy 2021 Feb 10;6(1):58. （共同通讯作者，IF 18.187）
14. Xu WP, Cui YL, Chen LL, Ding K, Ding CH, Chen F, Zhang X\*, Xie WF\*. Deletion of Sox9 in the liver leads to hepatic cystogenesis in mice by transcriptionally downregulating Sec63. Journal of Pathology, 2021 May;254(1):57-69（通讯作者，IF 7.996）
15. Xu WP, Wang XH, Wu SP, Shi PM, Tan Y, Guo YB, Zeng X, Xie WF. The prevalence and associated factors of simple hepatic cysts in Shanghai: a population-based cross-sectional study. Chinese Medical Journal, 2021 Jan 5;134(10):1248-1250.（通讯作者, IF2.628）
16. Zeng X, Sheng X, Wang PQ, Xin HG, Guo YB, Lin Y, Zhong JW, He CZ, Yin J, Liu TT, Ma WJ, Xiao X, Shi PM, Yuan ZL, Yang L, Ma X, Xu JM, Shen XZ, Yang CQ, Zhu X, Lv NH, Xie WF\*. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis. Hepatol Int. 2021, 15(1), 155-165. (通讯作者，IF 6.047)
17. Cai LY, Chen SJ, Xiao SH, Sun QJ, Ding CH, Zheng BN, Zhu XY, Liu SQ, Yang F, Yang YY, Zho B, Luo C, Zhang X, Xie WF\*. Targeting p300/CBP attenuates hepatocellular carcinoma progression through epigenetic regulation of metabolism. Cancer Research. 2021 Feb 15;81(4):860-872.（通讯作者， IF 12.701）
18. Wang J, Tian X, Ning BF, Wang XH, Yuan ZL, Li BB, Shi B, Xie WF. Clinical characteristics and prognosis of inflammatory fibroid polyp in the gastrointestinal tract: a series of 9 cases and literature review. J Dig Dis. 2020 Dec;21(12):737-740 （通讯作者，IF 2.325）
19. Guixé-Muntet S, Zhu CP, Xie WF, Gracia-Sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics. Pharmacol Ther. 2020 Nov;215:107626 (共同通讯作者，IF 12.31)
20. Lin L, Jian J, Song CY, Chen F, Ding K, Xie WF, Hu PF. SHP-1 ameliorates nonalcoholic steatohepatitis by inhibiting proinflammatory cytokine production. FEBS Lett. 2020 Sep;594(18):2965-2974.共同通讯作者，IF 4.124）
21. Dong Y, Chi X, Hai H, Sun L, Zhang M, Xie WF, Chen W. Antibodies in the breast milk of a maternal woman with COVID-19. Emerging Microbes & Infections. 2020 Dec;9(1):1467-1469. doi: 10.1080/22221751.2020.1780952. （共同通讯作者，IF 7.136）
22. Song ST, Shi J, Wang XH, Guo YB, Hu PF, Zhu F, Zeng X, Xie WF. Prevalence and risk factors for gallstone disease: A population-based cross-sectional study. J Dig Dis. 2020 Apr;21(4):237-245. doi: 10.1111/1751-2980.12857. （通讯作者，IF 2.325）
23. Hu Y, Zhang B, Shi X, Ning B, Shi J, Zeng X, Liu F, Chen JD, Xie WF. Ameliorating Effects and Autonomic Mechanisms of Transcutaneous Electrical Acustimulation in Patients With Gastroesophageal Reflux Disease. Neuromodulation. 2020 Dec;23(8):1207-1214. （通讯作者，IF 4.722）
24. Xu WP, Liu JP, Feng JF, Zhu CP, Yang Y, Zhou WP, Ding J, Huang CK, Cui YL, Ding CH, Zhang X, Lu B, Xie WF. miR-541 potentiates the response of human hepatocellular carc.inoma to sorafenib treatment by inhibiting autophagy. Gut. 2020 Jul;69(7):1309-1321.（通讯作者，IF 23.059）
25. Zeng X, Zhang LY, Liu Q, Lu CH, Wei J, Shi ZW, Huang WR, Qu LH, Xu F, Wang XH, Shi PM, Tan Y, Tan W, Yuan ZL, Xia CY, Liu YL, Xie WF. Combined Scores from the Encephal App Stroop Test, Number Connection Test B, and Serial Dotting Test Accurately Identify Patients With Covert Hepatic Encephalopathy. Clin Gastroenterol Hepatol. 2020 Jun;18(7):1618-1625.e7 （通讯作者，IF 11.382）
26. Zheng BN, Ding CH, Chen SJ, Zhu K, Shao J, Feng J, Xu WP, Cai LY, Zhu CP, Duan W, Ding J, Zhang X, Luo C, Xie WF. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α. Theranostics. 2019 Apr 13;9(9):2606-2617. (通讯作者，IF 8.579)
27. Zeng X, Li XX, Shi PM, Zhang YY, Song Y, Liu Q, Wei L, Bajaj JS, Zhu YH, Li Y, Gu Y, Xie WF, Liu YL. Utility of the Encephal App Stroop Test for covert hepatic encephalopathy screening in Chinese cirrhotic patients. J Gastroenterol Hepatol. 2019 Oct;34(10):1843-1850 (共同通讯作者，IF 3.437)
28. Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: Pros and cons. J Dig Dis. 2019 Mar;20(3):122-126.. (通讯作者，IF 1.736)
29. Wang P, Lei S, Wang X, Xu W, Hu P, Chen F, Zhang X, Yin C, Xie W. MicroRNA-134 Deactivates Hepatic Stellate Cells by Targeting TGF-β Activated Kinase 1-Binding Protein 1. Biochem Cell Biol. 2019 Oct;97(5):505-512. (通讯作者，IF 2.460)
30. Deng X, Zhang X, Li W, Feng RX, Li L, Yi GR, Zhang XN, Yin C, Yu HY, Zhang JP, LuB, Hui L, Xie WF\*. Chronic liver injuries induce the reprogramming of biliary epithelial cells to hepatocytes. Cell Stem Cell. 2018 Jul 5;23(1):114-122. (通讯作者，IF 21.464)
31. Wen LZ, Ding K, Wang ZR, Ding CH, Lei SJ, Liu JP, Yin C, Hu PF, Ding J, Chen WS, Zhang X, Xie WF\*. SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression.Cancer Research. 2018, 78(16):4680-4691. (通讯作者，IF 8.378)
32. Xu WP, Wang ZR, Zou X, Zhao C, Wang R, Shi PM, Yuan ZL, Yang F, Zeng X, Wang PQ, Sultan S, Zhang Y, Xie WF. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein evaluates liver function and predicts prognosis in liver cirrhosis. J Dig Dis. 2018;19(4):242-253. (通讯作者，IF 1.62)
33. Ding CH, Yin C, Chen SJ, Wen LZ, Ding K, Lei SJ, Liu JP, Wang J, Chen KX, Jiang HL, Zhang X, Luo C, Xie WF\*. The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1. Mol Cancer. 2018;17(1):63. (通讯作者，IF 10.679)
34. Wang W, Yao LJ, Shen W, Ding K, Shi PM, Chen F, He J, Ding J, Zhang X, Xie WF\*. FOXA2 alleviates CCl4-induced liver fibrosis by protecting hepatocytes in mice. Sci Rep. 2017;7:15532. （通讯作者，IF 4.259）
35. Ni Q, Ding K, Wang KQ, He J, Yin C, Shi J, Zhang X, Xie WF\*, Shi YQ\*. Deletion of HNF1α in hepatocytes results in fatty liver-related hepatocellular carcinoma in mice. FEBS Lett. 2017; 591:1947-1957. （共同通讯作者，IF 3.623）
36. Feng LM, Lei SJ, Zeng X, Wang PQ, Chen RT, Wang J, Sheng X, Shi PM, Yuan ZL, Xie WF\*. The evaluation of non-invasive multi-slice spiral computed tomography-based indices for the diagnosis and prognosis prediction of liver cirrhosis. J Dig Dis. 2017;18(8):472-479. （通讯作者，IF 1.887）

**5.获奖情况：**

1. 2014年，提高肝癌外科疗效的关键技术体系的创新和应用，中华人民共和国国务院，国家科技进步奖二等奖，2014-5-25301-2-01-R02

2. 2014年，肝脏“炎-癌”演变机制及防治研究，上海市人民政府，上海市科技进步奖一等奖，20144013-1-D01

3. 2012年，第二军医大学肝癌临床与基础集成化研究创新团队，中华人民共和国国务院，国家科技进步奖创新团队奖，2012-J- 207-1-02

4. 2009年，肝纤维化发病机制及治疗研究，上海市人民政府，上海市科技进步奖一等奖，20094196-1-R01

**6.发明专利：**

1. HNF4α诱导分化治疗人体恶性实体瘤 国家发明专利 ZL200810034200.3 授权日2011-9-28

2. 肝细胞核因子1α治疗人体恶性实体瘤 国家发明专利 ZL201010559047.3 授权日 2013-11-23

3. 肝细胞核因子1α治疗慢性肝病的用途 国家发明专利 ZL201110043321.6 授权日：2015-02-18

4. 阿尔维林在制备预防或治疗门脉高压症的药物中的应用 国家发明专利 ZL201810090563.2 授权日：2020-06-05

5. 五羟色胺受体1A在制备治疗门脉高压症药物的应用 PCT国际专利 PCT/CN2019/072124 公开日：2019-08-08

1. **主要学术兼职**

1.中华医学会消化病学分会常委（2018年）

2.中华医学会消化病学分会肝胆疾病学组组组长（2020年）

3．上海市医学会消化系病专业委员会前任主任委员（2020）

4. 上海市医师协会消化内科医师分会副会长（2018）

4．《中华消化杂志》总编辑（2019）

5．《Journal of Digestive Diseases》副主编（2019）

**8.联系方式**：weifenxie@medmail.com.cn